Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection.

Autor:	Chiari EF; Secretory IgA, Inc, Ann Arbor, Michigan, USA., Weiss W; Preclinical Services, University of North Texas Health Science Center-College of Pharmacy, Fort Worth, Texas, USA., Simon MR; Secretory IgA, Inc, Ann Arbor, Michigan, USA.; Allergy and Immunology Section, William Beaumont Hospital, Royal Oak, Michigan, USA.; Department of Medicine, Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA.; Departments of Internal Medicine and Pediatrics (Clinical Emeritus), Wayne State University School of Medicine, Detroit, Michigan, USA., Kiessig ST; PreviPharma, GmbH, Mannheim, Germany., Pulse M; Preclinical Services, University of North Texas Health Science Center-College of Pharmacy, Fort Worth, Texas, USA., Brown SC; Secretory IgA, Inc, Ann Arbor, Michigan, USA., Gerding HR; PreviPharma, GmbH, Mannheim, Germany., Mandago M; PreviPharma, GmbH, Mannheim, Germany., Gisch K; tcgBIOMICS, GmbH, Bingen, Germany., von Eichel-Streiber C; tcgBIOMICS, GmbH, Bingen, Germany.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2021 Oct 28; Vol. 224 (8), pp. 1394-1397.
DOI:	10.1093/infdis/jiab087
Abstrakt:	Coadministration of human secretory IgA (sIgA) together with subtherapeutic vancomycin enhanced survival in the Clostridioides difficile infection (CDI) hamster model. Vancomycin (5 or 10 mg/kg × 5 days) plus healthy donor plasma sIgA/monomeric IgA (TID × 21 days) or hyperimmune sIgA/monomeric IgA (BID × 13 days) enhanced survival. Survival was improved compared to vancomycin alone, P = .018 and .039 by log-rank Mantel-Cox, for healthy and hyperimmune sIgA, respectively. Passive immunization with sIgA (recombinant human secretory component plus IgA dimer/polymer from pooled human plasma) can be administered orally and prevents death in a partially treated CDI hamster model. (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu